Cas no 1405-20-5 (Polymyxin B sulfate)
Polymyxin B sulfate Chemical and Physical Properties
Names and Identifiers
-
- polymyxin B standard solution
- polymyxin B sulfate usp
- Polymyxin B sulfate salt
- Polymyxin B Sulphate
- Polymyxin B solution
- Polymyxin B sulfate
- Polymyxin B
- Polymyxin B 2,5-SULFATE
- Polymyxin B (PMB)
- Polymyxin B (sulfate)
- POLYMYXIN B SULFATE CELL CULTURE REAGENT
- AEROSPORIN
- APPLISORB
- MASTIMYXIN
- MYP SUPPLEMENT
- POLYMIXIN B SULFATE
- POLYMIXIN B SULPHATE
- PolymyxinBSulfate(sterile,non-sterile)
- PolymyxineBsulfate
- N-[3-Amino-1-[[1-[[3-amino-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]propyl]carbamo
- N-[3-Amino-1-[[1-[[3-amino-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]propyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]propyl]-6-methyl-octanamide sulfuric acid
- Poly-RX
- sufuric acid
- Polymixin B sulfate salt
- Polymyxin-B-sulphate
- Polymixin B-sulfate
- Aerosporin;PMB;Poly-RX
- SPECTRUM1500492
- HMS502E14
- HFMDLUQUEXNBOP-UHFFFAOYSA-N
- HMS2092A07
- HMS1920J04
- BCP12700
- NSC757278
- s1395
- C55H96N16O13.2H2SO4
- I559
- Polymixin B sulfate, Cell Culture Reagent
- AB2000085
- Listeria
- Polymycin B sulfate
- Polymyxin B Sulfate manufacturer
- Listeria monocytogenes Selective Supplement I
- N-[4-Amino-1-({1-[(4-amino-1-oxo-1-{[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-isobu
- MFCD00131991
- NS00020581
- (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide;suluric acid
- KS-1428
- A807660
- N-[4-Amino-1-({1-[(4-amino-1-oxo-1-{[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-isobutyl-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]amino}-2-butanyl)amino]-3-hydroxy-1-oxo-2-butanyl}amino)-1-oxo-2-butanyl]-6-methyloctanamide sulfate (salt)
- SR-05000002074-2
- 1405-20-5
- AKOS015895662
- CCG-39724
- Pharmakon1600-01500492
- PMB
- CHEBI:201398
- SR-05000002074
- FT-0654126
- 1405-20-5, 4135-11-9 (free base)
- CHEBI:201575
- N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide;sulfuric acid
- NCGC00094763-01
- NCGC00094763-02
- SR-05000002074-1
- N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide;suluric acid
- N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl
- USP grade pound not inverted exclamation markY6,000 USP units/mg
- POLYMYXIN B SULFATE; SULFURIC ACID
-
- MDL： MFCD30489731
- Inchi： 1S/C56H98N16O13.H2O4S/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79;1-5(2,3)4/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80);(H2,1,2,3,4)
- InChI Key： HFMDLUQUEXNBOP-UHFFFAOYSA-N
- SMILES： S(=O)(=O)(O)O.O=C1C(CC(C)C)NC(C(CC2C=CC=CC=2)NC(C(CCN)NC(C(CCNC(C(C(C)O)NC(C(CCN)NC(C(CCN)N1)=O)=O)=O)NC(C(CCN)NC(C(C(C)O)NC(C(CCN)NC(CCCCC(C)CC)=O)=O)=O)=O)=O)=O)=O
Computed Properties
- Exact Mass: 1300.72000
- Monoisotopic Mass: 1202.75
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 20
- Hydrogen Bond Acceptor Count: 22
- Heavy Atom Count: 90
- Rotatable Bond Count: 29
- Complexity: 2240
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 10
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 574
- Surface Charge: 0
- Tautomer Count: 1001
Experimental Properties
- Color/Form: Colorless powder
- Density: 4.7100
- Melting Point: 233-243°C
- Boiling Point: 1345°C
- Flash Point: No data available
- Solubility: H2O: 50?mg/mL
- Water Partition Coefficient: Soluble in water at 50mg/ml/n
- PSA: 573.64000
- LogP: 2.54990
- Merck: 7573
- Specific Rotation: -78.0° ~ -82.0° (c=2, H2O)
- Sensitiveness: Sensitive to light
- Solubility: Soluble in 40% ethanol solution, soluble in water. Almost insoluble in organic solvents such as ether, ketone, ester and hydrocarbon
- Vapor Pressure: No data available
Polymyxin B sulfate Security Information
-
Symbol:
- Prompt：warning
- Signal Word：Warning
- Hazard Statement： H302
- Warning Statement： P264-P270-P301+P312+P330-P501
- Hazardous Material transportation number：3249
- WGK Germany：3
- Hazard Category Code： 22
- Safety Instruction： S22-S24/25
- FLUKA BRAND F CODES：3-8-10
- Regulatory Condition Code：Class Q (sugars, alkaloids, antibiotics, hormones)
- RTECS：TR1150000
-
Hazardous Material Identification：
- Hazard Level：6.1(b)
- Packing Group：III
- Risk Phrases：R22
- Storage Condition：2-8°C
- HazardClass：6.1(b)
- PackingGroup：III
Polymyxin B sulfate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| BAI LING WEI Technology Co., Ltd. | 116739-1G |
Polymyxin B sulfate, >6500 IU/mg, suitable for cell culture |
1405-20-5 | 1G |
￥ 544 | 2022-04-26 | ||
| BAI LING WEI Technology Co., Ltd. | 116739-5G |
Polymyxin B sulfate, >6500 IU/mg, suitable for cell culture |
1405-20-5 | 5G |
￥ 1898 | 2022-04-26 | ||
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | P1923-5G |
Polymyxin B Sulfate |
1405-20-5 | 5g |
￥1590.00 | 2024-04-17 | ||
| TRC | P689400-500mg |
Polymyxin B Sulfate |
1405-20-5 | 500mg |
$ 80.00 | 2023-09-06 | ||
| TRC | P689400-1g |
Polymyxin B Sulfate |
1405-20-5 | 1g |
$ 91.00 | 2023-09-06 | ||
| TRC | P689400-2.5g |
Polymyxin B Sulfate |
1405-20-5 | 2.5g |
$ 164.00 | 2023-09-06 | ||
| TRC | P689400-5g |
Polymyxin B Sulfate |
1405-20-5 | 5g |
$265.00 | 2023-05-17 | ||
| TRC | P689400-10g |
Polymyxin B Sulfate |
1405-20-5 | 10g |
$396.00 | 2023-05-17 | ||
| TRC | P689400-25g |
Polymyxin B Sulfate |
1405-20-5 | 25g |
$724.00 | 2023-05-17 | ||
| MedChemExpress | HY-A0248-500mg |
Polymyxin B Sulfate |
1405-20-5 | 98.12% | 500mg |
￥500 | 2024-04-20 |
Polymyxin B sulfate Suppliers
Audited Supplier
Audited Supplier
Polymyxin B sulfate Related Literature
-
Xingya Wei,Bangjun Han,Renzheng Gu,Weimin Geng,Naiyun Gao RSC Adv. 2023 13 21537
Additional information on Polymyxin B sulfate
Recent Advances in Polymyxin B Sulfate (1405-20-5) Research: Key Findings and Implications
Polymyxin B sulfate (CAS: 1405-20-5) remains a critical antibiotic in the treatment of multidrug-resistant Gram-negative bacterial infections, particularly those caused by Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Despite its nephrotoxicity and neurotoxicity concerns, the lack of effective alternatives has sustained its clinical relevance. Recent studies have focused on optimizing its therapeutic efficacy, mitigating adverse effects, and exploring novel formulations. This research brief synthesizes the latest findings (2022–2024) on Polymyxin B sulfate, highlighting its mechanisms, resistance patterns, and emerging delivery systems.
A 2023 study published in Antimicrobial Agents and Chemotherapy elucidated the role of Polymyxin B sulfate in disrupting bacterial outer membranes via lipid A binding, with new structural insights revealing conformational flexibility that enhances its bactericidal activity. Concurrently, research in Journal of Controlled Release demonstrated the efficacy of liposomal-encapsulated Polymyxin B sulfate in reducing nephrotoxicity by 40% in murine models while maintaining therapeutic plasma concentrations. These advancements underscore the potential of nanotechnology to improve safety profiles.
Resistance mechanisms have also been a focal point. A 2024 genomic analysis (Nature Microbiology) identified plasmid-encoded mcr-10 genes in clinical isolates, conferring cross-resistance to Polymyxin B sulfate and colistin. This finding necessitates revised surveillance protocols. Meanwhile, combination therapies with β-lactams or carbapenems have shown synergistic effects, reducing required Polymyxin B doses by 30–50% in vitro (Clinical Infectious Diseases, 2023).
Emerging formulations include inhalable dry powders for pulmonary infections (Phase II trials, 2024) and topical gels for wound care, both leveraging Polymyxin B sulfate’s broad-spectrum activity. Regulatory updates from the FDA and EMA now recommend therapeutic drug monitoring (TDM) for all systemic Polymyxin B treatments, reflecting updated pharmacokinetic/pharmacodynamic models. These developments position Polymyxin B sulfate as a continually evolving therapeutic, bridging gaps in antimicrobial resistance crises.
